Arynta Solution
NDC Package 24338-019-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Arynta (lisdexamfetamine dimesylate oral) solution is lisdexamfetamine is used to treat attention deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments. This formulation utilizes a solution delivery system. Marketed by Azurity Pharmaceuticals, Inc., this product is identified by NDC 24338-019 and is authorized under FDA application NDA219847.

Identification & Billing

NDC Package Code
24338-019-01
Package Description
1 BOTTLE in 1 CARTON / 100 mL in 1 BOTTLE
Product Code
24338-019
11-Digit Billing Format
24338001901
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Arynta
Non-Proprietary Name
Lisdexamfetamine Dimesylate Oral
Substance Name
Lisdexamfetamine Dimesylate
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
LISDEXAMFETAMINE DIMESYLATE 10 mg/mL
Pharmacologic Class
Usage Information
Lisdexamfetamine is used to treat attention deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments. It may help to increase the ability to pay attention, stay focused, and stop fidgeting. Lisdexamfetamine may also be used to treat binge eating disorder (BED). It may help to reduce the number of binge eating days. This medication is a stimulant. It is thought to work by restoring the balance of certain natural chemicals (neurotransmitters) in the brain. This medication is not recommended for use for weight loss due to the risk of serious side effects.
DEA Schedule
Schedule II (CII) Substances

Regulatory & Marketing

Labeler Name
Azurity Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA219847
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-20-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 24338-019-01 identifies a specific commercial package of 1 bottle in 1 carton / 100 ml in 1 bottle of Arynta, a human prescription drug labeled by Azurity Pharmaceuticals, Inc.. This solution is formulated for oral use and contains lisdexamfetamine dimesylate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Azurity Pharmaceuticals, Inc. on March 20, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Lisdexamfetamine is used to treat attention deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments. It may help to increase the ability to pay attention, stay focused, and stop fidgeting. Lisdexamfetamine may also be used to treat binge eating disorder (BED). It may help to reduce the number of binge eating days. This medication is a stimulant. It is thought to work by restoring the balance of certain natural chemicals (neurotransmitters) in the brain. This medication is not recommended for use for weight loss due to the risk of serious side effects.

How is this Azurity Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 24338001901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
24338-019-01
11-Digit CMS (5-4-2)
24338-0019-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.